Management of myelodysplastic syndromes: 2008 update.

about

Infections in myelodysplastic syndromes New treatments for myelodysplastic syndromes Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study.Myocardial remodeling: cellular and extracellular events and targets.

P2860

Q26859275-BDFA33D9-F176-46D4-B239-A2FA36E587FF Q34549290-B13949AA-9570-4883-876B-0AD0FB7DEE1C Q35018552-27A1447A-F565-4C80-B0BE-491334C46A5C Q35168352-5CBED080-47B6-468F-8EDB-B185FD1D9A8E

P2860

Management of myelodysplastic syndromes: 2008 update.

Item

http://www.wikidata.org/entity/Q37108489

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Management of myelodysplastic syndromes: 2008 update.

@en

Management of myelodysplastic syndromes: 2008 update.

@nl

type

Item

label

Management of myelodysplastic syndromes: 2008 update.

@en

Management of myelodysplastic syndromes: 2008 update.

@nl

prefLabel

Management of myelodysplastic syndromes: 2008 update.

@en

Management of myelodysplastic syndromes: 2008 update.

@nl

P1476

Management of myelodysplastic syndromes: 2008 update

@en

P2093

Bart L Scott

http://www.w3.org/2001/XMLSchema#string

Eli Estey

http://www.w3.org/2001/XMLSchema#string

P2860

The World Health Organization (WHO) classification of the myeloid neoplasms

Proposals for the classification of the myelodysplastic syndromes

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

International scoring system for evaluating prognosis in myelodysplastic syndromes

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome.

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes.

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

P304

1344-1352

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19086598

http://www.w3.org/2001/XMLSchema#string

P932

2647329

http://www.w3.org/2001/XMLSchema#string

Management of myelodysplastic syndromes: 2008 update.

about

P2860

P2860

Management of myelodysplastic syndromes: 2008 update.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932